Katsuumi, Goro http://orcid.org/0000-0003-1291-4814
Shimizu, Ippei
Suda, Masayoshi http://orcid.org/0000-0002-3415-6236
Yoshida, Yohko
Furihata, Takaaki
Joki, Yusuke
Hsiao, Chieh-Lun
Jiaqi, Liang
Fujiki, Shinya
Abe, Manabu
Sugimoto, Masataka http://orcid.org/0000-0001-8737-8097
Soga, Tomoyoshi
Minamino, Tohru http://orcid.org/0000-0003-1627-6151
Funding for this research was provided by:
Ministry of Education, Culture, Sports, Science and Technology (23H05487, 22K18389, 19K07316)
Japan Agency for Medical Research and Development (JP20gm1110012, 21zf0127003s0201)
Article History
Received: 11 May 2023
Accepted: 2 May 2024
First Online: 30 May 2024
Competing interests
: T.M. discloses research funds and remuneration for lectures from Mitsubishi Tanabe Pharma Corporation. Canagliflozin was provided by Mitsubishi Tanabe Pharma Corporation. The funder of the study had no role in the design and conduct of the study, the collection, management, analysis and interpretation of the data, the preparation, review or approval of the manuscript, and the decision to submit the manuscript for publication. The other authors declare no competing interests.